Janux Therapeutics
11099 Torrey Pines Rd. Suite 290
La Jolla
CA
92037
United States
Tel: 858-750-4731
Website: http://www.januxrx.com/
36 articles about Janux Therapeutics
-
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/8/2024
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
-
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
2/29/2024
Janux Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
-
Janux Therapeutics Announces Proposed Public Offering of Common Stock
2/27/2024
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.
-
Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.
-
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
2/26/2024
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced positive updated clinical data for both of its clinical programs.
-
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
2/20/2024
Janux Therapeutics, Inc. today announced it will host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February 26th, 2024, at 4:30PM ET.
-
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
1/8/2024
Janux Therapeutics, Inc. today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
-
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
11/7/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the third quarter ended September 30, 2023, and provided a business update.
-
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
8/8/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the second quarter ended June 30, 2023, and provided a business update.
-
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
7/17/2023
Janux Therapeutics, Inc. today announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock.
-
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
7/17/2023
Janux Therapeutics, Inc. today announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC) and provided a pipeline update.
-
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
6/5/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.
-
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
5/9/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
-
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
4/24/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced that Janux management will participate at two upcoming investor conferences and be available for 1x1 meetings.
-
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
4/20/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the first patient has been dosed at City of Hope in a Phase 1 clinical trial of JANX008 in subjects with advanced or metastatic solid tumors including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
-
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/10/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
-
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
2/14/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen's 43rd Annual Health Care Conference and be available for 1x1 meetings from March 6 to 8, 2023 in Boston.
-
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
12/27/2022
Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.
-
Janux Therapeutics to Present at Upcoming Investor Conferences in November
11/22/2022
Janux Therapeutics, Inc. today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings.